Results 291 to 300 of about 268,778 (321)

Genetic data do not provide evidence that lower sclerostin is associated with increased risk of atherosclerosis: comment on the article by Zheng et al

Arthritis &Rheumatology, EarlyView.
James R. Staley, Olga Giannakopoulou, Gill Holdsworth, Martin Armstrong   +3 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Rheumatic diseases detected in patients presenting with uveitis. [PDF]

North Clin Istanb
Ozturk E, Inel TY, Kaya M, Sen G.
europepmc   +1 more source

Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic ...
Austin M. Wheeler, Joshua F. Baker, Thomas R. Riley IV, Tate M. Johnson, Yangyuna Yang, Punyasha Roul, Katherine D. Wysham, Grant W. Cannon, Gary Kunkel, Gail Kerr, Dana P. Ascherman, Paul Monach, Andreas Reimold, Scott Matson, Jill A. Poole, Michael J. Duryee, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England   +18 more
wiley   +1 more source

sCD40 and sCD40L as candidate biomarkers of rheumatic diseases: a systematic review and meta-analysis with meta-regression. [PDF]

Front Immunol
Zinellu A, Mangoni AA.
europepmc   +1 more source

Guidelines for the management of the foot affected by rheumatoid arthritis [PDF]

, 2010
Bowen, C, Dagg, A, Davies, S, Graham, A, Longrigg, K, Lyons, C, Williams, AE   +6 more
core  

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options.
Thuong Trinh‐Minh, Cuong Tran‐Manh, Andrea‐Hermina Györfi, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang, Meik Kunz, Helena Arozenius, Lars Pettersson, Sam Lindgren, Christina Wenglén, Jörg H. W. Distler   +12 more
wiley   +1 more source

Elevated Fcy receptor expression augments pro-inflammatory macrophage phagocytosis in systemic sclerosis and associated rheumatic diseases. [PDF]

Rheumatology (Oxford)
Hukara A, Bonazza GA, Tabib T, Micheroli R, Jordan S, Bürki K, Rudnik M, Ciurea A, Distler O, Lafyatis R, Błyszczuk P, Kania G.   +11 more
europepmc   +1 more source

RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings. [PDF]

Rheumatol Int
von der Decken CB, Kleinert S, Englbrecht M, Karberg K, Gauler G, Ronneberger M, Rapp P, Schuch F, Wendler J, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Welcker M, Bartz-Bazzanella P.   +13 more
europepmc   +1 more source